Clinically, HER2+ BC patients with high levels of circCDYL2 exhibit rapid relapse after anti-HER2 therapy, as well as a shorter disease-free survival and OS compared to those with low circCDYL2 levels [133]. Here, ERBB2 is linked to breast cancer.